Day One Biopharmaceuticals

Day One Biopharmaceuticals is a biotechnology company that focuses on developing new cancer therapies for patients of all ages. The company understands that advances in cancer research now enable drug developers to identify children and adults who may benefit from the same medicine. They develop new therapies that meet the critical needs of people of all ages living with cancer starting from the biology of childhood cancer.

Day One Biopharmaceuticals also focuses its efforts to bring the best medicines to families receiving the life-altering news of a new cancer diagnosis and the need for a treatment plan. It prioritizes programs that can be rapidly brought to market for both younger and older patients. The company's goal is to license and acquire the most promising products from research institutions as well as for biotechnology and pharmaceutical companies.

Day One Biopharmaceuticals headquartered in United States, North America, operates in the Biotechnology, Health Care, Pharmaceutical, Biopharma sector. The company focuses on Biotechnology and has secured $55.0B in funding across 80 round(s). With a team of 11-50 employees, Day One Biopharmaceuticals is actively contributing to advancements in Biotechnology. Their latest funding round, Post-IPO Equity - Day One Biopharmaceuticals, raised $175.0M. Discover more about their projects, partnerships, and impact on our platform.